# Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

> **NCT01126138** · PHASE3 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 200 (estimated)

## Conditions studied

- Carcinoma, Invasive Ductal, Breast

## Interventions

- **DRUG:** Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine
- **DRUG:** Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine

## Key facts

- **NCT ID:** NCT01126138
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-07
- **Primary completion:** 2015-05
- **Final completion:** 2015-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2011-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01126138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01126138, "Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01126138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*